---
title: "Merck hits record high after Argus hikes target to $170 on cancer vaccine progress"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296933246.md"
description: "Merck (MRK.US) rose 2% to a record $154.51 as Argus raised its target to $170, citing strong progress on its personalized mRNA cancer vaccine."
datetime: "2026-08-25T15:06:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296933246.md)
  - [en](https://longbridge.com/en/news/296933246.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296933246.md)
generator: "portal-rs"
---

# Merck hits record high after Argus hikes target to $170 on cancer vaccine progress

默克 (MRK.US) 盘中涨超 2%，现报 154.51 美元，股价创历史新高。

近期多家华尔街机构上调默克目标价。Argus Research 将目标价从 145 美元上调至 170 美元，维持买入评级；Barclays、Wells Fargo、JPMorgan 和 Scotiabank 等机构也相继跟调。Goldman Sachs 此前将目标价上调至 160 美元并维持买入评级。公司与 Moderna 联合开发的个性化 mRNA 癌症疫苗 intismeran 在黑色素瘤三期临床试验中达到无复发生存率主要终点，成为推动机构看好默克长期增长潜力的核心催化。默克近期公布的季度业绩也超出市场共识预期。

不过，联邦法院驳回了默克对《通胀削减法案》联邦医疗保险药品价格谈判计划的诉讼挑战，裁决确认了对不合规行为的严厉处罚，包括高达销售额 185.71% 至 1,900% 的消费税，可能对公司长期收入前景构成压力。

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Merck (MRK), Why Is Its Latest Update Raising Bigger Questions?](https://longbridge.com/en/news/298090109.md)
- [NewEdge Advisors LLC Purchases 41,950 Shares of Merck & Co., Inc. $MRK](https://longbridge.com/en/news/298434406.md)
- [Merck & Co., Inc. $MRK Shares Bought by Saudi Central Bank](https://longbridge.com/en/news/298130170.md)
- [Merck & Co., Inc. $MRK Stock Holdings Decreased by Secure Asset Management LLC](https://longbridge.com/en/news/297891447.md)
- [Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study](https://longbridge.com/en/news/298317967.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**